Various studies have concluded that human umbilical cord tissue-derived mesenchymal stem cells (hUCT-MSCs), which are similar to the Elite Cells™ we use at NovaCell Institute by Belleza, can regulate the immune system, and reduce systemic inflammation. These effects may occur in patients with overactive or underactive immune systems, and/or systemic inflammation who undergo our Frailty of Aging treatments.
A recent phase II clinical trial from the University of Miami on mesenchymal stem cell therapy for aging frailty using allogeneic mesenchymal stem cells (hMSCs) concluded that: “…Treated groups had remarkable improvements in physical performance measures and inflammatory biomarkers, both of which characterize the frailty syndrome…”
Extensive studies conducted on mice have revealed promising effects of growth differentiation factor 11 (GDF11) derived from human umbilical cord tissue-derived mesenchymal stem cells (hUCT-MSCs).
These findings suggest that GDF11 has the remarkable potential to reverse various aging effects that impact the body as it grows older.
Specifically, research indicates that GDF11 can effectively reduce the thickening of heart muscle, a common condition associated with aging that often leads to cardiovascular complications.
Furthermore, this potent factor has been observed to promote the growth of new blood vessels, a crucial process for maintaining healthy circulation and overall organ function.
Prof. Dr. Ernst von Schwarz is a world-renowned researcher and clinical and academic cardiologist, who has published more than 150 scientific articles in international peer-reviewed journals, several books’ chapters, and books. He is also a sought-after speaker at international scientific conferences worldwide, an expert on stem cell therapy and research, and a public figure in medical media.
My Dad in his early nineties was treatedm and it was like he got a new lease on life. He’s almost 100 now.
There's no need to collect stem cells from the patient's hip bone or fat while they are under anesthesia. This can be especially upsetting for small children and their parents.
Research shows that mesenchymal stem cells from umbilical cord tissue are stronger than those from other sources.
No need to administer chemotherapy drugs like granulocyte-colony stimulating factor (G-CSF or GCSF) to stimulate the bone marrow to produce granulocytes and stem cells, and release them into the bloodstream.
Since HUCT mesenchymal stem cells are immune system privileged, cell rejection is not an issue and Human Leukocyte Antigen (HLA) matching is not necessary.
The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened and selected.
Allogeneic stem cells can be administered multiple times over the course of days in uniform dosages that contain high cell counts.
Umbilical cord tissue is a valuable resource that contains many mesenchymal stem cells. These stem cells can turn into different types of cells and are important for healing and medical treatments because they can grow and change into specialized cells.
We use Elite Cells™. Years-long retrospective analysis of patient outcomes has enabled us to identify and select the best cell lines for use in our patients.
One of our staff physicians will assign a stem cell treatment protocol after you have submitted all requested medical information and received approval. Your recommended protocol may differ from the example given below:
Note: Includes Hilton hotel room with breakfast, WIFI, transportation from and to the airport with VIP airport gate service and expedited customs clearance upon arrival.
No stem cell product from any source, including the patient’s own, is approved by the US FDA to treat frailty of aging.
However, human umbilical cord tissue-derived mesenchymal stem cells that were isolated and grown in our laboratory to create master cell banks have been used in the United States under US FDA regulation.
The body’s immune system is unable to recognize umbilical cord-derived mesenchymal stem cells as foreign, and therefore they are not rejected.
Human umbilical cord tissue stem cells have been administered tens of thousands of times at the NovaCell Institute, and there has never been a single instance of rejection (graft vs. host disease). As a matter of fact, allogeneic (not the patient’s own) mesenchymal stem cells are approved to treat graft vs. host disease in Canada and New Zealand.
Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than “older” cells, such as those found in the fat, and therefore, they are considered to be more “potent”.
The adult stem cells used to treat frailty of aging at the NovaCell Institute come from human umbilical cord tissue (allogeneic mesenchymal). These stem cells are expanded at Barranquilla, Colombia’s state-of-the-art laboratory.
The mesenchymal stem cells we use are recovered from donated umbilical cords following normal, healthy births.
Each mother has her medical history screened and is tested for infectious diseases. Proper consent is received from each family prior to donation.
All umbilical cord-derived stem cells are screened for infectious diseases to International Blood Bank Standards before they are cleared for use in patients.
Only a small percentage of donated umbilical cords pass our rigorous screening process.
Proper follow-up is an essential part of stem cell therapy. Our primary goal is to ensure you or your loved one progressing safely. Regular follow-up also enables us to evaluate efficacy and improve our treatment protocols based on observed outcomes.
Therefore, our medical staff will be contacting you after 1 month, 3 months, 6 months, 9 months, and 1 year to monitor your child’s progress.
You can APPLY TODAY to find out if you are eligible for treatment, and a patient coordinator will reach out to will arrange for a free screening and consultation.
NovaCell Regenerative Medicine by Belleza
Cra 59B 81-143
Barranquilla, Colombia
Outside or Inside US Call:
Phone: +1 (754) 333-6754
Copyright 2026, NovaCell Institute in Barranquilla, Colombia. All rights reserved.
